Last reviewed · How we verify
ADXS31-142
Listeria monocytogenes-based immunotherapy targeting MUC1
Listeria monocytogenes-based immunotherapy targeting MUC1 Used for Non-small cell lung cancer, Ovarian cancer.
At a glance
| Generic name | ADXS31-142 |
|---|---|
| Sponsor | Advaxis, Inc. |
| Drug class | Cancer vaccine |
| Target | MUC1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
ADXS31-142 is a live, attenuated Listeria monocytogenes-based immunotherapy that targets the MUC1 antigen, which is overexpressed in various cancers.
Approved indications
- Non-small cell lung cancer
- Ovarian cancer
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |